Abstract
Triple-negative breast cancer (TNBC) accounts for nearly one-quarter of all breast cancer cases, but effective targeted therapies for this disease remain elusive because TNBC cells lack the expression of the most common three receptors seen in other subtypes of breast cancers. The medium-term diagnosis of breast cancers is essential for development and prognosis. According to reports, patients with TNBC may be converted to a positive epidermal growth factor receptor 2(HER-2) after chemotherapy, and trastuzumab treatment will have a better prognosis. Therefore, it is important to accurately quantify the expression of HER-2 in breast cancer cells. Herein, we design a red fluorescent Au25 probe synthesized with BSA-biotin as the ligand, which is accurately quantified by HER-2 primary antibody-biotin using the avidin system. The quantitative detection of the expression of HER-2 in breast cancers is helpful for the companion diagnostic of breast cancer treatment and provides follow-up treatment.
Highlights
Triple-negative breast cancer (TNBC) is characterized by tumors that do not express estrogen receptors (ER), progesterone receptors (PR) or HER-2
The fluorescence of the bovine serum albumin (BSA)-biotin-Au25 clusters was stable at room temperature in the buffered media, and there was no significant change over 90 days (Figure 1e,f)
Companion diagnostics for TNBC have gained momentum in recent years, demonstratCompanion diagnostics have gained momentum in recent demoning clear benefits including notfor only choosing a personalized treatment planyears, for patients, strating clear benefits including choosing a personalized treatment plan forfor pabut reducing the use of drugs
Summary
TNBC is characterized by tumors that do not express estrogen receptors (ER), progesterone receptors (PR) or HER-2. There is still a lack of effective treatment strategies, due to the lack of ER/PR/HER-2 expression, making TNBC unsusceptible to current targeted therapies, resulting in a high mortality and recurrence rate. As people’s interest in precision medicine has been growing, the principle of companion diagnostics has gained more and more attention among laboratory professionals, clinicians and even patients. Chemotherapeutic drugs such as paclitaxel are commonly used in the clinical treatment of TNBC, but studies have shown that the use of these chemotherapeutic drugs has a low pathological complete remission (PCR) rate of only 25.9% [3].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
